NCT03150056 2022-08-10
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Terminated
GlaxoSmithKline
Debiopharm International SA
GlaxoSmithKline
AstraZeneca